Theravance Biopharma shareholders approve merger with Zymeworks

Theravance Biopharma shareholders approved its approximately $929 million acquisition by Zymeworks, with 40.99 million votes in favor versus 8,671 against. Holders will receive $17.00 per share in cash plus a contingent value right for 80% of net proceeds from any ampreloxetine licensing or monetization over 10 years. The shareholder vote satisfies a merger closing condition, and the transaction is expected to close around September 23, 2026, subject to remaining conditions.

Analysis

With the shareholder vote cleared and the expected close less than a week away, TBPH is no longer a fundamental biotech beta vehicle; it is a closing-risk instrument. The relevant question is the annualized spread to the fixed cash consideration after assigning little-to-no near-term value to the CVR, since its realization depends on a decade-long, uncertain monetization process. Unless TBPH trades at a meaningful discount to the cash component, residual return is unlikely to compensate for operational closing risk, settlement timing, or a low-probability regulatory/contractual failure.

ZYME should be assessed as the economic acquirer, not simply as the corporate survivor. The market may initially reward pipeline diversification, but the principal 1-3 month catalyst is disclosure around financing, pro forma cash runway, transaction costs, and the accounting treatment of acquired assets; any incremental equity issuance or reduced runway would pressure ZYME regardless of strategic logic. Over 6-18 months, the key issue is whether the acquired platform creates fundable development optionality or merely raises the cash burn needed to support an earlier-stage portfolio.

The underappreciated asymmetry is the CVR: it can create a headline valuation premium for TBPH holders while being too contingent and illiquid to justify much value in an arbitrage model. Value it separately using probability-weighted licensing scenarios, net of the 80% sharing formula and a high discount rate; treating it as a near-cash sweetener risks overpaying for the stock. The thesis is falsified if closing is delayed beyond the stated timetable, a new financing/security filing changes ZYME's capital structure, or TBPH's cash spread widens rather than converges as settlement approaches.

Key Decisions for Investors

• Event-driven: buy TBPH only if the discount to the $17 cash component exceeds approximately $0.20-$0.30 per share after borrow, commissions, and a conservative zero value for the CVR; target is cash consideration at closing over the next 1-3 weeks. Avoid initiating if the spread is narrower, as annualized optics can mask limited absolute upside.
• Do not short ZYME mechanically against TBPH unless the merger consideration mechanics create a direct hedge; this is a cash deal plus CVR, so a TBPH/ZYME pair leaves material idiosyncratic ZYME pipeline and financing exposure. Treat ZYME as a separate post-close fundamental position.
• Set a filing alert for pro forma liquidity, financing commitments, equity issuance, and revised R&D guidance from ZYME. If transaction-related disclosures imply materially less than 18 months of cash runway without financing, consider a 1-3 month tactical ZYME short or put spread, sized small given biotech binary upside.
• Mark the CVR at a heavily discounted optionality value rather than including it in merger-arb carry. Reassess only upon a disclosed third-party licensing process, asset sale, or development milestone that provides independently observable valuation evidence.